Fort Worth, Texas—With many providers turning to direct oral anticoagulants (DOACs) for treatment of venous thromboembolism (VTE) in adults with cancer, oncology pharmacists must know about the optimal regimens for these challenging patients.
“Many providers are using DOACs as an alternative agent because of their advantages in convenience, cost and quality of life” compared with subcutaneous low-molecular-weight heparin (LMWH), said Prakirthi Yerram, PharmD, a